Coming to grips with bone loss.
Marx
Jean
J
D019386:Alendronate / Q000627:therapeutic use; D000818:Animals; D015519:Bone Density; D016723:Bone Remodeling; D001842:Bone and Bones / Q000502:physiology*; D002352:Carrier Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D004963:Estrenes / Q000494:pharmacology / Q000627:therapeutic use; D004967:Estrogens / Q000378:metabolism; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D010006:Osteoblasts / Q000502:physiology; D010010:Osteoclasts / Q000502:physiology; D010024:Osteoporosis / Q000188:drug therapy* / Q000503:physiopathology* / Q000517:prevention & control; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D010281:Parathyroid Hormone / Q000502:physiology / Q000627:therapeutic use; D044162:Parathyroid Hormone-Related Protein / Q000494:pharmacology / Q000627:therapeutic use; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D011960:Receptors, Estrogen / Q000378:metabolism; D000068296:Risedronic Acid; D015398:Signal Transduction; D019379:Teriparatide / Q000627:therapeutic use / Q000633:toxicity; D014807:Vitamin D / Q000008:administration & dosage / Q000502:physiology
C468666:4-estren-3,17-diol; D002352:Carrier Proteins; D004963:Estrenes; D004967:Estrogens; D008562:Membrane Glycoproteins; D010281:Parathyroid Hormone; D044162:Parathyroid Hormone-Related Protein; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D011960:Receptors, Estrogen; C505686:TNFRSF11A protein, human; C505688:TNFSF11 protein, human; D019379:Teriparatide; D014807:Vitamin D; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate